Very large database of lipids: Rationale and design

Clinical Cardiology

Volumn 36, Issue 11, 2013, Pages 641-648

  Martin, Seth S ^a   Blaha, Michael J ^a   Toth, Peter P ^b   Joshi, Parag H ^a   McEvoy, John W ^a   Ahmed, Haitham M ^a   Elshazly, Mohamed B ^a   Swiger, Kristopher J ^a   Michos, Erin D ^a   Kwiterovich, Peter O ^a   Kulkarni, Krishnaji R ^c   Chimera, Joseph ^c   Cannon, Christopher P ^d   Blumenthal, Roger S ^a   Jones, Steven R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CGH MEDICAL CENTER   (United States)

^c Atherotech Diagnostics Inc   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN;

ANALYZER; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DATA BASE; DYSLIPIDEMIA; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; PEER REVIEW; STUDY DESIGN;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; DATA INTERPRETATION, STATISTICAL; DATA MINING; DATABASES AS TOPIC; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84888015779     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22214     Document Type: Article

References (34)

1. Finking G, Hanke H,. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997; 135: 1-7.
2. Lopez AD, Murray CC,. The global burden of disease, 1990-2020. Nat Med. 1998; 4: 1241-1243.
3. World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life. Geneva, Switzerland. http://www.who.int/whr/2002/en/ whr02-en.pdf. Accessed July 3, 2013.
4. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372: 224-233.
5. National Cholesterol Education Program,. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
6. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
7. Genest J, McPherson R, Frohlich J, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009; 25: 567-579.
8. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-1818.
9. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458-2473.
10. Chrispin J, Martin SS, Hasan RK, et al. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease [published online ahead of print May 30, 2013]. Clin Cardiol. doi: 10.1002/clc.22147.
11. Carroll MD, Kit BK, Lacher DA, et al. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA. 2012; 308: 1545-1554.
12. Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood). 2012; 31: 2276-2285.
13. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357: 2109-2122.
14. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367: 2089-2099.
15. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 998-1006.
16. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012; 126: 2283-2292.
17. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013; 381: 40-46.
18. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012; 367: 1891-1900.
19. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation. 2012; 126: 2408-2417.
20. Kohli P, Desai NR, Giugliano RP, et al. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012; 35: 385-391.
21. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012; 380: 2007-2017.
22. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
23. Brook RD, Kansal M, Bard RL, et al. Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention. Clin Cardiol. 2005; 28: 534-537.
24. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007; 50: 1735-1741.
25. Kulkarni KR,. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006; 26: 787-802.
26. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013; 62: 732-739.
27. Lauer MS,. Time for a creative transformation of epidemiology in the United States. JAMA. 2012; 308: 1804-1805.
28. Kwiterovich PO, Gidding SS,. Universal screening of cholesterol in children. Clin Cardiol. 2012; 35: 662-664.
29. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006; 259: 247-258.
30. AIM-HIGH Investigators, BodenWE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365: 2255-2267.
31. Ponda MP, Huang X, Odeh MA, et al. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Circulation. 2012; 126: 270-277.
32. Ponda MP, Dowd K, Finkielstein D, et al. The short-term effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2012; 32: 2510-2515.
33. Huang Y, Yu X, Millican D, et al. The measurement of lipids currently and 9 years ago-which is more associated with carotid intima-media thickness? Clin Cardiol. 2012; 35: 512-517.
34. Cross DS, McCarty CA, Steinhubl SR, et al. Development of a multi-institutional cohort to facilitate cardiovascular disease biomarker validation using existing biorepository samples linked to electronic health records [published online ahead of print June 5, 2013]. Clin Cardiol. doi: 10.1002/clc.22146]